GGI
CRNX icon

GordonMD Global Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History

GordonMD Global Investments’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Hold
126,985
– – 2.3% 15
2026
Q1 		$4.61M Sell
126,985
-97,150
-43% -$4.34M 3.21% 13
2025
Q4 		$10.4M Buy
+224,135
New +$9.98M 7.48% 4

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GordonMD Global Investments's CRNX Position: Q2 2026 in Review

GordonMD Global Investments held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 126,985 shares worth $4.75M. The position accounts for 2.3% of the portfolio, ranked #15.

GordonMD Global Investments first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.4M in Q4 2025. 265 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • GordonMD Global Investments held 126,985 shares of Crinetics Pharmaceuticals worth $4.75M as of Q2 2026.
  • GordonMD Global Investments left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 2.3% of GordonMD Global Investments's portfolio in Q2 2026, its #15 holding.
  • GordonMD Global Investments first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • GordonMD Global Investments's Crinetics Pharmaceuticals position peaked at $10.4M in Q4 2025.
  • 265 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on GordonMD Global Investments's 13F filing for Q2 2026, filed 14 Aug 2026.